News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Active Biotech AB Interim Report Jan-Sep 2007
November 8, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LUND, SWEDEN--(Marketwire - November 08, 2007) - * Laquinimod - recruitment to the Phase III program ongoing - results from the extension study strengthen Phase II data - new positive preclinical data presented - new indications under evaluation
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Mergers & acquisitions
Lilly-Verve Proxy Filing Reveals Tumult After Departure of FDA’s Marks
June 26, 2025
·
4 min read
·
Annalee Armstrong
Deals
Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal
June 26, 2025
·
1 min read
·
Annalee Armstrong
Cardiovascular disease
Novartis Makes Potential $750M+ Bet Per Cardiovascular Disease Target in Another Flagship Pact
June 26, 2025
·
2 min read
·
Tristan Manalac
Layoff Tracker
Bayer’s BlueRock Lays Off 50 in Streamlining Effort
June 26, 2025
·
148 min read
·
BioSpace Editorial Staff
